REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5 (b) - AbbVie Inc

AbbvieAnnouncement

15/04/2020 12:25

RNS Number : 7424J
  
Bank of America Merrill Lynch
  
15 April 2020
  
 


FORM 38.5(b)
 
IRISH TAKEOVER PANEL



DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013



DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY 
 




1.


KEY INFORMATION










Name of exempt principal trader 






Bank of America, N.A., Proprietary







Company dealt in 






AbbVie Inc







Class of relevant security to which the

dealings being disclosed relate(Note 1) 






Common - US00287Y1091







Date of dealing 






14/04/2020



 




2.


INTERESTS AND SHORT POSITIONS









(a)


Interests and short positions (following dealing) in the class of relevant security

dealt in (Note 2) 







Class of relevant security: Common


US00287Y1091








Long


Short




Number


%


Number


%







(1) 


Relevant securities 






1,723,212


0.117% 


2,814,419


0.191 % 







(2) 


Derivatives (other than options): 






3,685,147


0.25% 


2,715,552


0.184% 







(3) 


Options and agreements to purchase/sell: 






0


0% 


0


0% 




Total


5,408,359


0.366% 


5,529,971


0.374% 



 




(b)


Interests and short positions in relevant securities of the company, other than the

class dealt in (Note 2) 








Class of relevant security: 












Long


Short




Number


%


Number


%







(1) 


Relevant securities 






0 


0% 


0 


0% 







(2) 


Derivatives (other than options): 






0 


0% 


0 


0% 







(3) 


Options and agreements to purchase/sell: 






0 


0% 


0 


0% 




Total


0 


0% 


0 


0% 








3.


DEALINGS (Note 3)








(a)


Purchases and sales







Purchase/sale


Number of relevant securities


Price per unit (Note 4) 




Purchase


  131,571 


80.3 USD         




Purchase


          36 


81.26 USD         




Purchase


          26 


81.46 USD         




Purchase


          25 


81.51 USD         




Purchase


          27 


81.76 USD         




Purchase


          24 


81.79 USD         




Purchase


          43 


81.86 USD         




Purchase


          25 


81.92 USD         




Purchase


          41 


82.03 USD         




Purchase


            9 


82.04 USD         




Purchase


          29 


82.08 USD         




Purchase


          36 


82.12 USD         




Purchase


     3,358 


82.13 USD         




Purchase


          36 


82.18 USD         




Purchase


          36 


82.21 USD         




Purchase


          62 


82.25 USD         




Purchase


          64 


82.28 USD         



 



Purchase/sale


Number of relevant securities


Price per unit (Note 4) 




Sale


  131,095 


80.3 USD         




Sale


          30 


81.26 USD         




Sale


          34 


81.28 USD         




Sale


          45 


81.65 USD         




Sale


          45 


81.86 USD         




Sale


          30 


81.92 USD         




Sale


          42 


81.94 USD         




Sale


          33 


81.96 USD         




Sale


     6,002 


82.13 USD         




Sale


          31 


82.16 USD         




Sale


          31 


82.18 USD         




Sale


          45 


82.22 USD         




Sale


          32 


82.26 USD         




Sale


          45 


82.29 USD         




Sale


          32 


82.38 USD         



 




(b)


Derivatives transactions (other than options transactions) 








Product name,

e.g. CFD 


Nature of transaction

(Note 5)


Number of relevant securities
(Note 6)


Price per unit

(Note 4)




Swaps


Increasing a Short Position


129,175


80.3 USD



 




(c)


Options transactions in respect of existing relevant securities 








(i)


Writing, selling, purchasing or varying







Product name, e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc


Expiry date


Option money paid/ received per unit (Note 4)




N/A


N/A


N/A


N/A


N/A


N/A


N/A



 




(ii)


Exercising








Product name,

e.g. call option 


Number of securities


Exercise price per

unit (Note 4)




N/A


N/A


N/A



 




(d)


Other dealings (including transactions in respect of new securities) (Note 3) 








Nature or transaction
(Note 7)


Details


Price per unit

(if applicable) (Note 4)




N/A


N/A


N/A



 




4.


OTHER INFORMATION




 

Agreements, arrangements or understandings relating to options or derivatives 

 



Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting rights

or future acquisition or disposal of any relevant securities to which any derivative

referred to on this form is referenced. If none, this should be stated. 




None 



 




Is a Supplemental Form 38.5(b) attached? (Note 8)


No




 



Date of disclosure


15/04/2020




Contact name


Tolu Tade




Telephone number


+44207 996 3410




Name of offeree/offeror with which connected 


AbbVie Inc




Nature of connection (Note 9)


Advisor to - AbbVie Inc



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEBELFFBZLLBBF